Cancer Therapy News and Research

RSS

Anti-growth factor drugs raise hope and concern for treatment of children's eye diseases

A new class of antibody drugs may provide a powerful new tool for the treatment of eye diseases in children, but specialists need to be alert for the possibility of serious side effects, according to an editorial in the August Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus), published by Elsevier.

3 Aug 2009

Tarceva shown to extend survival in advanced non-small cell lung cancer when used after initial chemo

OSI Pharmaceuticals, Inc. has announced further results from the Phase III SATURN study showing that Tarceva® (erlotinib) extended the survival of patients with advanced non-small cell lung cancer (NSCLC) when used as single agent, maintenance therapy in patients who did not progress following first-line treatment with platinum-based chemotherapy.

2 Aug 2009

Nanoparticles show potential as part of new therapy for advanced ovarian cancer

Nanoparticle delivery of diphtheria toxin-encoding DNA selectively expressed in ovarian cancer cells reduced the burden of ovarian tumors in mice, and researchers expect this therapy could be tested in humans within 18 to 24 months, according to a report in Cancer Research, a journal of the American Association for Cancer Research.

30 Jul 2009

Oregon hospital building boom slows down

"Oregon's hospital spending boom is winding to a close," as hospitals cut back on projects, Portland Business Journal reports. "Portland-area hospitals have opened, started construction on, or announced expansions costing at least $1.3 billion in the past 18 months. Projects include cancer treatment centers, cardiac units and pediatric care facilities.

28 Jul 2009

Nanodiamonds hold promise for wound-healing applications

Bacterial infection is a major health threat to patients with severe burns and other kinds of serious wounds such as traumatic bone fractures. Recent studies have identified an important new weapon for fighting infection and healing wounds: insulin.

27 Jul 2009

NHS on the cards for an ailing Australian health system

A new report is recommending a Federal takeover of the Australian public health and dental system - the report by the National Health and Hospitals Reform Commission (NHHRC) says the health system is under strain and in need of a new prescription.

27 Jul 2009

Nanoparticle Trojan horse for ovarian cancer

In a feat of trickery, Dartmouth Medical School immunologists have devised a Trojan horse to help overcome ovarian cancer, unleashing a surprise killer in the surroundings of a hard-to-treat tumor.

19 Jul 2009

"Drops" of gold that burn tumors

At a technical breakfast, Romain Quidant presented his research into the detection and treatment of cancer using gold nanoparticles illuminated with laser light. Quidant, who was recently awarded the Fresnel Prize 2009 that recognizes the highest level of excellence amongst emerging researchers in the field of photonics, is an ICREA researcher at the UPC's Institute of Photonic Sciences (ICFO) and a fellow of the Cellex Foundation Barcelona.

16 Jul 2009

New alliance for discovery of WNT pathway inhibitors to be used in cancer therapy

Cancer Research Technology (CRT), Merck Serono, a division of Merck KGaA, Darmstadt, Germany, Cancer Research UK, Cardiff University and The Institute of Cancer Research (ICR) are set to begin a major new research collaboration for the first time. This will provide substantial investment in research on the WNT signalling pathway in the hope of finding new drug targets.

15 Jul 2009

Study finds survival rates from GIST improving among African-Americans

New research published in the July issue of the Journal of the American College of Surgeons reveals that African Americans with gastrointestinal stromal tumors (GIST), a rare cancer that begins in the wall of the gastrointestinal tract, now have survival rates equivalent to those of Caucasians. Prior to 2000, African Americans were more likely to develop GIST and less likely to undergo surgical treatment for this type of cancer.

14 Jul 2009

Overcoming the big ‘nanotech’ challenges

Whether in the fields of medicine, sustainable energy supply or environmental protection, without making use of nanotechnology we will not be capable of overcoming the challenges which the future presents. In parallel with these efforts, though, it is essential that we examine the new technology very carefully for potential risks, such as those presented by free nanoparticles.

14 Jul 2009

Health reformers shy from proposals that would limit treatment options

In a story headlined 'In Retooled Health-Care System, Who Will Say No?' the Washington Post reports: "Although Obama and his advisers have held up providers' spending patterns as the crux of the crisis, proposals in Washington go only so far in addressing the thorniest questions about who gets what care."

8 Jul 2009

High-intensity-focused ultrasound in the treatment of primary prostate cancer

An experimental cancer therapy for prostate cancer may be able to treat men without surgery and offer fewer side effects according to the results of a UK study published in the British Journal of Cancer.

7 Jul 2009

Senior breast cancer patients receive ‘chemo’ if treated in private practices

In a study to determine the non-medical factors that may be associated with the decision to treat nonmetastatic breast cancer, researchers at Columbia University Mailman School of Public Health evaluated the association between oncologist characteristics and the receipt of chemotherapy in elderly women with breast cancer and found that they were more likely to receive chemotherapy if treated by oncologists employed in a private practice.

7 Jul 2009

Potential new target for acute myeloid leukemia

Dr. John Dick, Senior Scientist at the Ontario Cancer Institute, the research arm of Princess Margaret Hospital, co-led a multinational team that has developed the first leukemia therapy that targets a protein, CD123, on the surface of cancer stem cells that drive acute myeloid leukemia (AML), which is an aggressive disease with a poor outcome.

6 Jul 2009